However, the intertumoral mutational landscape of SCLC is otherwise heterogeneous, with the frequency of other gene mutations dropping dramatically compared with TP53 and RB1. Compilation of multiple large datasets such as ours are valuable for exploring and categorizing this heterogeneity, and for assessing drivers of response and/or resistance to immunotherapy. Here, TP53 is linked to small cell lung carcinoma.